ACTC.OB has filed an Investigational New Drug (IND) Application with the US FDA to initiate a Phase I/II multicenter study Read more…
CUR filed an IND application with the FDA to begin a Phase I safety clinical trial for chronic spinal cord injury with its spinal cord stem cells. Read more…
Founder and Director of Research, Henry McCusker enters his tenth (10) year at Scimitar Equity with past experience in sell-side analysis, buy-side management, corporate management and due diligence.
I started this blog to add commentary, update news flow and insightful opinions that are intelligent, fit to print and SEC compliant.